表紙
市場調查報告書

潰瘍性大腸炎:開發中產品分析

Ulcerative Colitis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 264709
出版日期 內容資訊 英文 633 Pages
訂單完成後即時交付
價格
Back to Top
潰瘍性大腸炎:開發中產品分析 Ulcerative Colitis - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 633 Pages
簡介

潰瘍性大腸炎 (UC) ,由於主要大腸發生的慢性疾病,是發炎性腸道疾病的一種。由於特徵,有腸的潰瘍抽煙,遺傳,肝疾病,大腸癌症,憂鬱症,重度脫水等的要素。一般的症狀直出血,腹部痛,腹瀉等,治療有手術,胺基水楊酸藥 (ASA製藥) 的藥物治療,免疫調節療法和皮質類固醇的。

本報告提供潰瘍性大腸炎的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

潰瘍性大腸炎概要

治療藥的開發

潰瘍性大腸炎:治療藥的評估

開發潰瘍性大腸炎的治療藥的企業

藥物簡介

潰瘍性大腸炎:暫停中的計劃

潰瘍性大腸炎:開發中止的產品

潰瘍性大腸炎:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11614IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2019, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 18, 49, 34, 1, 67 and 19 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Ulcerative Colitis - Overview
  • Ulcerative Colitis - Therapeutics Development
  • Ulcerative Colitis - Therapeutics Assessment
  • Ulcerative Colitis - Companies Involved in Therapeutics Development
  • Ulcerative Colitis - Drug Profiles
  • Ulcerative Colitis - Dormant Projects
  • Ulcerative Colitis - Discontinued Products
  • Ulcerative Colitis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ulcerative Colitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Ulcerative Colitis - Pipeline by 4D Pharma Plc, H2 2019
  • Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2019
  • Ulcerative Colitis - Pipeline by AbGenomics International Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Abivax SA, H2 2019
  • Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Algernon Pharmaceuticals Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Alivio Therapeutics Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Allergan Plc, H2 2019
  • Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Alvotech ehf, H2 2019
  • Ulcerative Colitis - Pipeline by Am-Pharma BV, H2 2019
  • Ulcerative Colitis - Pipeline by Amgen Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Antibe Therapeutics Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Apidel SA, H2 2019
  • Ulcerative Colitis - Pipeline by Applied Molecular Transport LLC, H2 2019
  • Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Artelo Biosciences Inc, H2 2019
  • Ulcerative Colitis - Pipeline by AsiaBiome, H2 2019
  • Ulcerative Colitis - Pipeline by Asta Pharmaceuticals Co Ltd, H2 2019
  • Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H2 2019
  • Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2019
  • Ulcerative Colitis - Pipeline by Avexegen Therapeutics Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Axim Biotechnologies Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Bausch Health Companies Inc, H2 2019
  • Ulcerative Colitis - Pipeline by BioXpress Therapeutics SA, H2 2019
  • Ulcerative Colitis - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Ulcerative Colitis - Pipeline by Bridge Biotherapeutics Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Ulcerative Colitis - Pipeline by Celgene Corp, H2 2019
  • Ulcerative Colitis - Pipeline by Cellix Bio Pvt Ltd, H2 2019
  • Ulcerative Colitis - Pipeline by Celltrion Inc, H2 2019
  • Ulcerative Colitis - Pipeline by Chain Biotechnology Ltd, H2 2019
  • Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H2 2019
  • Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2019
  • Ulcerative Colitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Ulcerative Colitis - Pipeline by Circle33 LLC, H2 2019
  • Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2019
  • Ulcerative Colitis - Pipeline by Cristcot HCA LLC, H2 2019
  • Ulcerative Colitis - Pipeline by CrystalGenomics Inc, H2 2019

List of Figures

  • Number of Products under Development for Ulcerative Colitis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top